The unexpected arrival of a new life often disrupts deeply ingrained habits. For people who use cannabis, this change creates a profound internal conflict between the desire to protect the fetus and the difficulty of abandoning an established habit. The uncertainty surrounding this topic stems not only from a lack of clear information but also from a media narrative that often conflates scientific data with moral judgments. As professionals committed to holistic health, it is imperative to distinguish between what science says and what social prejudices dictate.
In brief
- Limited evidence: Studies on cannabis and pregnancy are scarce, often featuring small sample sizes and contradictory results regarding severe malformations.
- Primary risk: Low birth weight is more frequently associated with concurrent tobacco use than with cannabis itself.
- Category C: Pharmacologically, synthetic THC and sublingual cannabinoids fall into Category C (risk cannot be ruled out), suggesting caution but not an absolute prohibition in the absence of alternatives.
- Reproductive rights: In Spain, urine testing for cannabis in pregnant women and the subsequent social protocols violate fundamental rights if they are not applied with the same rigor to tobacco.
- Clinical approach: The recommendation should be neutral: abstinence is ideal when possible, but without stigmatizing or punishing those who are already pregnant.
The myth of safety and the reality of the data
We often hear that “no harm has been proven.” It is crucial to understand the logical difference between this statement and “it has been proven that there is no harm.” The absence of evidence for severe adverse effects (such as major congenital malformations) is not equivalent to proof of absolute safety. In pharmacology, especially during pregnancy, we operate under the precautionary principle: only strictly necessary substances should be administered.
The first weeks of embryonic development are critical. Organogenesis occurs between the second and eighth week, a phase when drugs have the highest teratogenic potential. Although some animal studies using massive doses of synthetic THC have shown abortions or malformations, these conditions do not replicate human recreational use or typical doses. However, this does not exempt us from caution.
The confusion of tobacco: a determining factor
One of the greatest obstacles to understanding the real risk is the common conflation of cannabis and tobacco use. Cigarette smoke contains carbon monoxide, nicotine, and other toxins that act as vasoconstrictors, drastically reducing blood flow to the placenta. This limits the supply of oxygen and nutrients to the fetus, leading to low birth weight.
In many epidemiological studies, it is nearly impossible to isolate the effect of cannabis from that of tobacco. When a user stops using cannabis but continues to smoke cigarettes, the cardiovascular risks to the baby persist. Therefore, attributing all neonatal health problems to cannabis without considering polysubstance use is a common methodological error that distorts the perception of risk.
Pharmacological classification and therapeutic use
To provide context, let us recall the safety categories in pregnancy (A, B, C, D, X). Medicinal cannabis, specifically synthetic THC (Marinol) and sublingual sprays (Sativex), are classified as Category C. This means there are animal studies showing adverse effects or a lack of robust human data. Their use is only justified if the benefits clearly outweigh the potential risks.
The indications for which these drugs are typically prescribed (chemotherapy-induced nausea, severe neuropathic pain, multiple sclerosis) are conditions that, in most cases, do not coexist with pregnancy or have safer alternative treatments. Therefore, their use during gestation is considered exceptional and must be evaluated on a case-by-case basis.
Recreational use: abstinence vs. reality
In the realm of recreational use, the standard medical recommendation is abstinence from conception or upon discovering the pregnancy. If a casual user discovers they are pregnant and stops using immediately, the risk that previous use will significantly affect fetal health is considered low. Cannabinoids remain in the body for weeks after stopping, but this does not necessarily imply toxic levels for the fetus.
Fertility can also be affected by cannabinoids due to their hormonal action, although this is more relevant in cases of intensive use or pre-existing infertility issues. For this reason, it is advisable to avoid cannabis while planning a pregnancy if there are difficulties in conceiving.
The ethical and legal problem: stigmatization vs. health
One aspect that cannot be ignored is the treatment of users within the Spanish healthcare system. At times, disclosing cannabis use leads to moral reproach, routine urine testing, and intervention by Social Services, labeling the patient as an “addict” or “high risk.”
This practice lacks scientific foundation if the same rigor is not applied to tobacco. Why penalize cannabis severely while ignoring the most widespread and harmful habit? Furthermore, there are cases where newborns are admitted to rule out withdrawal syndrome without real clinical evidence, based solely on the mother’s history.
The mother’s mental health is fundamental. Social stigma and institutional threats generate toxic stress, anxiety, and postpartum depression—factors that do have a proven impact on the child’s development. A human rights-based approach to harm reduction prioritizes education, psychological support, and non-discrimination over punishment.
Conclusion: toward compassionate medicine
Cannabis during pregnancy is a topic where pharmacology, medical ethics, and civil rights converge. Current science suggests that while there is no evidence of severe malformations like those caused by alcohol or heroin, there are subtle warning signs (low birth weight) linked primarily to polysubstance use with tobacco.
The prudent recommendation is to avoid use if possible. However, when this does not occur, the medical response must be empathetic and educational, not punitive. We must work to ensure that expectant mothers receive accurate information without fear of losing their rights or their dignity. True protection of the fetus begins with a healthy, informed mother who is free from stigma.
At Psiconáutica, we understand health as a balance between the body, the mind, and the social environment. We advocate for health policies that protect users without criminalizing them, always promoting the holistic well-being of the entire family.
